SP-0345: For the motion  by Verellen, D.
3rd ESTRO Forum 2015                                                                                                                                         S169 
 
patients are inoperable due due medical co-morbidities: local 
tumor control is achieved in >90% of the patients resulting in 
improved overall survival (OS). Based on the promising 
experiences in primary lung cancer and other cancer sites, 
SBRT is currently explored in the setting of oligo-metastatic 
disease. In this rather rare clinical setting, patients with a 
limited number of metastases (maximum 3-5) in a limited 
number of organs (1-2) are treated locally aiming at 
prolongation of disease-free interval, treatment-free interval 
and eventually overall survival. Despite the value of any local 
treatment in the metastatic setting has not been proven in 
randomized clinical trials, surgery is the guideline-
recommended treatment of choice in many cancers e.g. 
colorectal cancer or renal cell cancer. This presentation will 
outline the rational of using SBRT in the oligo-metastatic 
setting, give a summary of current evidence and compare 
SBRT with other local treatment options especially surgical 
resection. 
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SABR for oligometastatic disease is a favourite pastime for 
radiation oncologists looking for application of high precision 
hypofractionated conformal radiotherapy. This is often 
fuelled by interests in technology of treatment delivery not 
infrequently vested in equipment suited for this technique. 
Yet SABR is just one of a spectrum of local therapies for small 
lesions (which include surgery and thermal ablation) and 
evidence for benefit of real value to the patient is weak. 
There is reasonable consensus that SABR can achieve 
prolonged control of individual lesions with reasonable safety 
providing the lesions are small and the dose is delivered 
within radiation tolerance of the structure they are lodged 
in. However, evidence of real benefit for the patient in terms 
of prolonging survival and improving or maintaining quality of 
life is hard to come by. The problems include the lack of 
validated definition of oligometastatic disease, inevitable 
patient selection and the consequent reporting bias and the 
lack of randomised studies. In this setting, SABR for 
oligometastatic disease cannot be considered the standard of 
care. 
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Few evidences are available to justify the integration of 
stereotactic ablative radiotherapy (SABR) with current 
systemic approaches in metastatic disease, especially in the 
first-line setting. The use of SABR is supported by low-level 
evidence due to retrospective nature of published 
experiences, heterogeneous group of patients treated across 
studies, different techniques adopted, different dose and 
fractionation chosen, different endpoints evaluated, short 
follow-up, little or no data regarding late  and early late 
toxicity. 
Although in most cases very good rate of local control are 
reported with good toxicity profile, no large studies 
demonstrated the significant impact of SABR for 
oligometastases on disease-free and overall survival of 
patients. 
Prospective experience are strongly required to evaluate the 
potential impact of SABR in the context of standard systemic 
therapies in a homogeneous disease population, on improving 
progression-free survival, time to progression, and hopefully 
overall survival. An overview on the attractive challenge 
between technical innovation and clinical benefit. 
 
 
Teaching Lecture: Regional nodes radiotherapy in early 
breast cancer  
 
 
SP-0347   
Regional nodes radiotherapy in early breast cancer 
B.V. Offersen1 
1Aarhus University Hospital, Dept. Oncology, Aarhus C, 
Denmark  
 
Regional radiotherapy (RT) is generally offered to patients 
operated for node-positive early breast cancer (BC), in 
particular if >3 nodes are involved. Despite results from 
randomised trials indicating beneficial effect from regional 
RT in patients with 1-3 positive nodes (pN1) many of these 
patients are not offered regional RT routinely (Overgaard et 
al, NEJM 1997, Lancet 1999, R&O 2007, Ragaz et al, NEJM 
1997). The reluctance may be due to a relatively high 
incidence of loco-regional recurrences (LRR) and poor overall 
survival (OS) in the trials compared to retrospective studies 
in the same type of patients treated without regional RT in 
the same period. Recently the randomised MA.20 trial, which 
included 1832 patients (85% of the patients had pN1 disease) 
treated with breast conservation 2000 to 2007, confirmed the 
beneficial effect of regional RT (Whelan et al, ASCO 2011, 
abstract). Even node-negative patients operated for a medial 
or centrally located BC may have a survival gain from 
irradiating the internal mammary nodes (IMN) and medial 
supraclavicular (MS) nodes as demonstrated in the EORTC 
22922/10925 Trial (Poortmans et al, ECCO 2013, abstract). It 
is thus likely that the use of regional RT will increase with 
the publication of these 2 trials. 
A new group of patients is now being proposed as candidate 
for regional RT based on the AMAROS study (Donker et al, 
Lancet Oncol 2014). In that trial patients diagnosed with T1-2 
and sentinel node positive BC were randomised to axillary 
lymph node dissection (ALND) versus axillary RT. The 1425 
patients had an excellent and comparable loco-regional and 
distant control, but significantly more lymph oedema was 
seen in the ALND group favouring regional RT.  
There are several concerns when planning regional RT, and 
one is the decision on optimal target delineation. An ESTRO 
consensus for this is now published. Another concern is the 
decision about which lymph node levels are the relevant 
targets to be irradiated. The EORTC 22922/10925 Trial 
adressed this when randomising 4004 stage I-III patients to ± 
RT to the IMN and MS nodes, and showed a gain in 10 year 
DFS and MFS. The DBCG IMN study based on >3000 patients 
also showed an OS gain in node positive patients if the IMN 
were included in the RT fields (Thorsen et al, EBCC 2014, 
abstract). A third concern is dose and fractionation, because 
most studies have used 50 Gy/25 fr, but since the publication 
of a Canadian trial and the START Trial B more centres are 
now using hypofractionation based on 40-42,5 / 15-16 fr for 
regional RT despite only limited data support this. Of 
